In an analysis pooling crude OR of seven studies [61, 62, 77, 94, 97, 112, 115], it was observed that HER2+ breast cancer patients were significantly associated with better treatment response (OR 2.50; 95% CI 1.44–4.35; p=0.001). Here, ERBB2 is linked to breast carcinoma.